Avastin for CNV Secondary to Pattern Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00391144|
Recruitment Status : Unknown
Verified October 2006 by University of Trieste.
Recruitment status was: Recruiting
First Posted : October 23, 2006
Last Update Posted : October 23, 2006
The natural history of subfoveal CNV secondary to Pattern Dystrophy is little understood, but it seems that visual function may be preserved only in the short-term follow-up, with progressive deterioration thereafter.
Photodynamic therapy with verteporfin is the most studied therapeuthic option for this kindf of lesion, but unfortunately, this approach does not appear to guarantee long-term vision stabilization, and alternative therapies should be investigated.
|Condition or disease||Intervention/treatment||Phase|
|Choroidal Neovascularization Secondary to Pattern Dystrophy||Procedure: intravitreal triamcinolone injection of avastin (1.25 mg)||Phase 2 Phase 3|
Diagnosis of Pattern Dystrophy Diagnosis of subfoveal CNV Intravitreal injection of avastin (1.25 mg) in operating room under sterile condition.
Retreatment on the basis of the detection of disease progression and of lack of central retinal thickness reduction on OCT.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Intravitreal Avastin Injection for the Treatment of Choroidal Neovascularization Secondary to Pattern Dystrophy|
|Study Start Date :||July 2006|
|Study Completion Date :||October 2006|
- number of eyes with <15 letter loss (approximately <3 lines) at 6-month examination compared with the baseline value
- numeber of eyes with <15 letter loss at 12-month examinations, compared with the baseline value.
- CNV progression
- number of injections.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00391144
|Contact: Maurizio B Parodi, MD||+39 040 firstname.lastname@example.org|
|Contact: Giuseppe Ravalico, MD||+39 040 email@example.com|
|Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste||Recruiting|
|Trieste, TS, Italy, 34129|
|Contact: Giuseppe Ravalico, MD +39 040 772449 firstname.lastname@example.org|
|Principal Investigator:||Maurizio B Parodi, MD||Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste|
|Principal Investigator:||Pierluigi Iacono, MD||Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste|
|Study Director:||Giuseppe Ravalico, MD||Clinica Oculistica, Azienda Ospedaliero-Universitaria di Trieste|